# Sik-Kwan Chan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2788163/publications.pdf

Version: 2024-02-01

| 23 | 245 | 1307594 | 996975 |
|---|---|---|---|
| papers | citations | 7 h-index | 15 g-index |

| 23 | 23 | 23 | 295 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Refining TNM-8ÂM1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma. Oral Oncology, 2022, 126, 105736. | 1.5 | 4 |
| 2 | Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis. JTO Clinical and Research Reports, 2022, 3, 100322. | 1.1 | 3 |
| 3 | An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma. Cancers, 2022, 14, 1923. | 3.7 | 1 |
| 4 | Overall survival benefits of first-line treatments for Asian patients with advanced epidermal growth factor receptor-mutated non-small cell lung cancer harboring L858R mutation: A systematic review and network meta-analysis.. Journal of Clinical Oncology, 2022, 40, e21064-e21064. | 1.6 | 0 |
| 5 | Combined 18F-FDG and 11C-acetate positron emission tomography/computed tomography in staging and treatment decision in patients with hepatocellular carcinoma: A cost-effectiveness analysis.. Journal of Clinical Oncology, 2022, 40, e16176-e16176. | 1.6 | 0 |
| 6 | Antitumor activity of bintrafusp alfa in previously treated patients with recurrent or metastatic nasopharyngeal cancer (NPC): A single arm, prospective phase II trial.. Journal of Clinical Oncology, 2022, 40, e18029-e18029. | 1.6 | 1 |
| 7 | Sequential trans-arterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy (START-FIT) for locally advanced hepatocellular carcinoma: A single-arm, phase II trial.. Journal of Clinical Oncology, 2022, 40, 4091-4091. | 1.6 | 2 |
| 8 | Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis. Cancers, 2022, 14, 3362. | 3.7 | 1 |
| 9 | Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma. JAMA Network Open, 2021, 4, e2033761. | 5.9 | 27 |
| 10 | Incidence and Demographics of Nasopharyngeal Carcinoma in Cheung Chau Island of Hong Kongâ€”A Distinct Geographical Area With Minimal Residential Mobility and Restricted Public Healthcare Referral Network. Cancer Control, 2021, 28, 107327482110471. | 1.8 | 2 |
| 11 | First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers, 2021, 13, 931. | 3.7 | 26 |
| 12 | The Most Efficacious Induction Chemotherapy Regimen for Locoregionally Advanced Nasopharyngeal Carcinoma: A Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 626145. | 2.8 | 9 |
| 13 | Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinoma: A pooled analysis of two prospective studies. Oral Oncology, 2021, 114, 105158. | 1.5 | 7 |
| 14 | Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.. Journal of Clinical Oncology, 2021, 39, 6046-6046. | 1.6 | 0 |
| 15 | Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer. Frontiers in Oncology, 2021, 11, 651299. | 2.8 | 6 |
| 16 | Integrated palliative medicine in public oncology: a 10-year review. BMJ Supportive and Palliative Care, 2021, , bmjspcare-2021-002922. | 1.6 | 0 |
| 17 | Integrative Palliative Care Service Model Improved End-of-Life Care and Overall Survival of Advanced Cancer Patients in Hong Kong: A Review of Ten-Year Territory-Wide Cohort. Journal of Palliative Medicine, 2021, 24, 1314-1320. | 1.1 | 7 |
| 18 | Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy. Frontiers in Oncology, 2020, 10, 1417. | 2.8 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Lymphopenia and Radiation Dose to Circulating Lymphocytes With Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma. Advances in Radiation Oncology, 2020, 5, 880-888. | 1.2 | 35 |
| 20 | Phase II study of consolidative intensity-modulated radiation therapy following first-line palliative systemic chemotherapy for de novo previously untreated metastatic (M1) nasopharyngeal carcinoma.. Journal of Clinical Oncology, 2020, 38, 6524-6524. | 1.6 | 2 |
| 21 | Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes. British Journal of Cancer, 2019, 121, 690-698. | 6.4 | 19 |
| 22 | The addition of pretreatment plasma Epsteinâ€“Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. International Journal of Cancer, 2019, 144, 1713-1722. | 5.1 | 82 |
| 23 | Prognostic role of pretreatment plasma EBV DNA on stage III nasopharyngeal carcinoma staged by AJCC/UICC 8<sup>th</sup> edition TNM staging classification.. Journal of Clinical Oncology, 2018, 36, 6055-6055. | 1.6 | 0 |